AALAS advances responsible laboratory animal care and use to benefit people and animals

14.1.11

9190 Crestwyn Hills Dr Memphis, TN 38125-8538 (901) 754-8620 tax +901+753-0046

e-mail_into@aalas.org

February 7, 2003

Food and Drug Administration 5630 Fishers Lanes, Room 1061 Rockville, MD 20852

RE: Docket Number 02N-0452 Dockets Management Branch (HFB-305)

Dear Sir or Madam:

The American Association for Laboratory Animal Science (AALAS) is pleased to have the opportunity to provide comment to the Food and Drug Administration regarding Docket 02N-0452 Comment Request: New Drug and Biological Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. AALAS is an organization of laboratory animal scientists whose mission is to advance responsible care and use of laboratory animals to benefit people and animals. Therefore, AALAS is the premier forum for the exchange of information and expertise in the care and use of laboratory animals. AALAS membership consists of more than 11,000 clinical veterinarians, technicians, technologists, educators, and business people, researchers, administrators, animal producers and national and international AALAS plays a leadership role in helping to facilitate biomedical research through training, scientific programs, and advocacy roles whenever laboratory animals are used in research, teaching, and testing.

AALAS strongly supports the use of laboratory animals in biomedical research to discover and develop new drugs and biological products that benefit both humans and animals, provided the work is performed in a responsible and humane manner.

We encourage the FDA to support research studies that are conducted in full compliance with all applicable federal, state and local regulations. We promote work utilizing sound experimental design in scientifically controlled studies to minimize the number of laboratory animals used, yet with adequate statistical power and precision. Such studies are conducive to valid conclusions in the discovery and development of efficacious and safe drugs and biologicals.

LENGUINE COMMITTEE

President Cyribra & Pokow 1988 Admetsomidffeith Cir 8880 South WY

Vice President Gad A Heidbrink RESG Wheatfind WY

Vice President-Elect 181 The fifth Seathers Corner Streadpoint 1A

Secretary/Treasurer lack R. Hessler, DVV

Attorney at Law Thomas Lt. Boerschinger

District One
Stanley P Friebenberg DVM
smoot Shore sepublic
1-st Science St

Kathleen L. Smiler, USAS

District Two Ann Marie Dinkel BS RUSIG A Darritonis Crosi lira Sc

Leopold M. Yanas, Kr. Mt. No substitute School Al

District Three Discount L Bartlett (88.) vic National histories (Chauft (30) odd (80)

hiddth T. Snow, MRX 1 Mc sale De SID

District Four Margaret C. Flogan, Rt VC. Oak Envisor Indiana Sa

Darrell F. Hoskins, DVAL Separat Scathern less in 1(1) ships form in Eq. (3)

Kim Longnecker REMG

District Six James Michael Byrne, LNG

Rita E. Moore Exto 1501 X/S

District Seven Valen Lanstord REV.C.

Tetrora H. McGultev, MAC Basinet of rivor Medicine Houston (X

District Eight Janes J. Baer LIVM MS

Ardis K. Rosebern, BS Surfrancisco CA

EXECUTAT DIRECTOR Ann Tourigny Turner PhD CAF We encourage the FDA to support research that has strongly considered the use of scientifically valid alternatives to animal use in an effort to either reduce, refine, or replace animal models. In addition, we request you support animal studies where animals are cared for and used under the standards for animal care and use as outlined in the 1996 Institute for Laboratory Animal Research (ILAR), National Academy of Science publication *Guide for the Care and Use of Laboratory Animals*.

For further information about AALAS and our policy regarding animal care and use, you are encouraged to visit our website at www.aalas.org or you may contact us directly for more information.

Hua Klow DVM

Sincerely yours,

Cynthia A. Pekow, DVM

President, AALAS